Dianthus Therapeutics, Inc.
DNTH
$16.86
-$0.585-3.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -100.61% | -95.08% | -55.64% | -56.89% | -63.65% |
| Total Depreciation and Amortization | 14.96% | 16.06% | 45.18% | 124.10% | 69.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 205.85% | 355.52% | 302.23% | 377.83% | 177.73% |
| Change in Net Operating Assets | -85.39% | -107.22% | -120.13% | -108.84% | 219.74% |
| Cash from Operations | -118.87% | -112.09% | -84.86% | -62.27% | -21.99% |
| Capital Expenditure | 24.22% | 4.55% | 34.88% | -18.10% | 5.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -8,079.74% | -1,507.98% | -1,803.99% | -21.91% | 92.16% |
| Cash from Investing | -7,773.29% | -1,516.15% | -1,818.41% | -21.89% | 91.88% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | 100.00% | 100.00% | 100.00% |
| Issuance of Common Stock | -82.55% | 5,405,660.00% | 4,612,140.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -101.85% | -110.98% | -114.11% | -- | 3,744.61% |
| Cash from Financing | -89.20% | 91.37% | 52.47% | -- | 263.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -204.22% | -193.50% | -202.53% | 632.97% | 1,361.63% |